原发性干燥病:未满足需求、结局指标、治疗进展与健康经济影响的综述——来自NECESSITY创新健康倡议的启示
该综述描述了原发性干燥病(pSjD)的未满足需求、结局指标的科学效度、临床试验设计优化、治疗进展及临床改善与健康相关生活质量、质量调整生命年和经济获益的关系,源于欧盟资助的NECESSITY创新健康倡议学术-产业联合体项目,并介绍了正在验证的Sjögren's Tool for Assessing Response复合应答标准。
要点
- pSjD累及外分泌腺,伴高症状负担(口干、疲劳、疼痛)、系统特征和唾液腺功能障碍。
- B细胞过度活跃常见,黏膜相关淋巴组织淋巴瘤风险增加。
- NECESSITY联合体包含20个学术伙伴、1个患者团体伙伴和4个产业伙伴,患者领袖密切参与。
核心结论
- 该综述阐述了pSjD的未满足需求、结局指标科学效度、临床试验设计优化、治疗进展及临床改善与健康相关生活质量、质量调整生命年和经济获益的关系。
研究设计与样本
- 综述源于欧盟资助的NECESSITY创新健康倡议学术-产业联合体项目,并借鉴欧洲抗风湿病联盟干燥综合征工作组等的工作。
- NECESSITY联合体由20个学术伙伴、1个患者团体伙伴和4个产业伙伴组成,患者领袖密切参与。
- 在新结局指标Sjögren's Tool for Assessing Response复合应答标准的开发阶段,获得了欧洲药品管理局和美国食品药品监督管理局的专家建议。
主要发现
- pSjD是一种累及外分泌腺的自身免疫性风湿病,与高症状负担(口干、疲劳、疼痛)、系统特征和唾液腺功能障碍相关。
- B细胞过度活跃常见,黏膜相关淋巴组织淋巴瘤风险增加。
- Sjögren's Tool for Assessing Response复合应答标准正在通过NECESSITY IHI临床试验和产业申办试验进行验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary Sjögren's disease (pSjD) is an autoimmune rheumatic disease involving exocrine glands and associated with high symptom burden (dryness, fatigue, pain), systemic features and salivary gland dysfunction. B-cell hyperactivity is common, with an increased risk of mucosa-associated lymphoid tissue lymphoma. This review describes the unmet need, scientific validity of outcome measures, optimisation of clinical trial design, therapeutic advances and how clinical improvement relates to health-related quality of life, additional quality-adjusted life years and economic benefit in pSjD. It derives from the EU-funded Necessity IHI Academic-Industry collaborative Consortium project while also drawing on work by the European Alliance of Associations for Rheumatology Sjögren's task force and others. The NECESSITY Consortium, formed within the framework of the Innovative Health Initiative (IHI), comprises 20 academic partners, 1 patient group partner and 4 industry partners (NECESSITY; https://necessity-h2020.eu). Patient leaders have been closely involved, with expert advice obtained from the European Medicines Agency and the United States Food and Drug Administration during the development phase of a new outcome measure, the Sjögren's Tool for Assessing Response composite response criteria. This tool is now undergoing validation through the NECESSITY IHI clinical trial and industry-sponsored trials.
引用
- Bowman SJ, Seror R, Porcher R, et al. Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI). Ann Rheum Dis. 2025. PMID: 40527714. doi:10.1016/j.ard.2025.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。